Immunotherapy and Hyperprogression: Unwanted Outcomes, Unclear Mechanism.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 30397179.
- Also identified by DOI 10.1158/1078-0432.CCR-18-3144 and PMC identifier 6359946.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Hyperprogression (HP) is a recently defined clinical phenomenon in which patients treated with immunotherapy paradoxically exhibit rapid tumor growth. The mechanisms of hyperprogression remain ill-defined, although recent studies in this issue point to a possible role for Fc receptors in this process.<i>See related article by Lo Russo et al., p. 989</i>.
Medical subject headings
- Carcinoma, Non-Small-Cell Lung
- Lung Neoplasms